DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial.
We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT). Neither clinical rating scales nor psychometric tests revealed any improvement over 84 days with once-daily intranasal treatment with 2 different doses of DGAVP. We conclude that vasopressin-like peptides are not satisfactory therapeutic agents in DAT.
Wolters
E C
EC
Department of Neurology, Amsterdam Free University, The Netherlands.
Riekkinen
P
P
Lowenthal
A
A
Van der Plaats
J J
JJ
Zwart
J M
JM
Sennef
C
C
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic
D001127:Arginine Vasopressin; C015119:argipressin, des-GlyNH2(9)-